Potential small effector molecules restoring cellular defects due to sialic acid biosynthetic enzyme deficiency: Pathological relevance to GNE myopathy.
Biochem Pharmacol
; 223: 116199, 2024 05.
Article
in En
| MEDLINE
| ID: mdl-38604256
ABSTRACT
GNEM (GNE Myopathy) is a rare neuromuscular disease caused due to biallelic mutations in sialic acid biosynthetic GNE enzyme (UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase). Recently direct or indirect role of GNE in other cellular functions have been elucidated. Hyposialylation of IGF-1R leads to apoptosis due to mitochondrial dysfunction while hyposialylation of ß1 integrin receptor leads to altered F-actin assembly, disrupted cytoskeletal organization and slow cell migration. Other cellular defects in presence of GNE mutation include altered ER redox state and chaperone expression such as HSP70 or PrdxIV. Currently, there is no cure to treat GNEM. Possible therapeutic trials focus on supplementation with sialic acid, ManNAc, sialyllactose and gene therapy that slows the disease progression. In the present study, we analyzed the effect of small molecules like BGP-15 (HSP70 modulator), IGF-1 (IGF-1R ligand) and CGA (cofilin activator) on cellular phenotypes of GNE heterozygous knock out L6 rat skeletal muscle cell line (SKMGNEHz). Treatment with BGP-15 improved GNE epimerase activity by 40 % and reduced ER stress by 45 % for SKMGNEHz. Treatment with IGF-1 improved epimerase activity by 37.5 %, F-actin assembly by 100 %, cell migration upto 36 % (36 h) and atrophy by 0.44-fold for SKMGNEHz. Treatment with CGA recovered epimerase activity by 49 %, F-actin assembly by 132 % and cell migration upto 41 % (24 h) in SKMGNEHz. Our study shows that treatment with these small effector molecules reduces the detrimental phenotype observed in SKMGNEHz, thereby, providing insights into potential therapeutic targets for GNEM.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oximes
/
Piperidines
/
N-Acetylneuraminic Acid
/
Distal Myopathies
Limits:
Animals
Language:
En
Journal:
Biochem Pharmacol
Year:
2024
Document type:
Article
Affiliation country:
India
Country of publication:
United kingdom